Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Lung Cancer in HIV-positive Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NSCLC histologically (highly recommended) and/or cytologically confirmed, stage III (non-irradiable or inoperable) or stage IV (according to 2009 TNM classification), with other than predominantly squamous histology~* HIV seropositivity (previous or inaugural), irrespective of CD4 count or viral load~* Presence of at least one measurable lesion (RECIST v1.1)~* Subject having signed the informed consent form,~* Subject who, in the investigator's opinion, will be able to comply with the requirements and constraints of the study~* Age ≥ 18 years ≤ 75 years,~* WHO performance status: 0, 1 or 2~* Weight loss ≤ 10% of total body weight in the month before inclusion~* Estimated life expectancy ≥ 1 month,~* Covered by health insurance~Exclusion Criteria:~* Bronchial cancer already treated (other than endoscopic deobstruction)~* Cancer which is amenable to surgery or radiation (curative),~* Squamous cell lung cancer or mixed small cell and non-small cell cancer, small cell lung cancer~* Creatinine clearance (MDRD) \< 45 mL/min~* Severe hypersensitivity to any of the study products or excipients~* Severe disease or uncontrolled systemic disease (unstable or decompensated respiratory disease, cardiac, hepatic or renal disease, uncontrolled opportunistic infection)~* Significant abnormality in CBC-platelets (Hb \<9 g/dL, PNN \<1500 / mm3, platelets \< 100,000 / mm3)~* Significant abnormality in liver tests (AST, ALT \> 3x ULN, and \<5 in case of liver metastases),~* Women of childbearing age without effective contraception; pregnant or breastfeeding women~* Subject who cannot take vitamin B12, folic acid or corticosteroids~* Diffuse interstitial pneumonia~* Any geographical situation or psychological condition that precludes full understanding and compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).